ClearPoint Neuro任命Paul Larson博士为首席医疗官,从2026年1月起生效。 ClearPoint Neuro appoints Dr. Paul Larson as Chief Medical Officer effective January 2026.

ClearPoint Neuro已任命Paul Larson博士为首席医疗官,从2026年1月起生效。 ClearPoint Neuro has appointed Dr. Paul Larson as its Chief Medical Officer effective January 2026. 作为长期的神经外科导航顾问和专家, 拉森博士已经监督或执行了100多项细胞和基因治疗程序, 并继续在UCSF和Banner Health担任临床和研究角色. A longtime advisor and expert in neurosurgical navigation, Dr. Larson has overseen or performed over 100 cell and gene therapy procedures and continues his clinical and research roles at UCSF and Banner Health. 他将支持该公司对帕金森氏病、癫痫和稀有遗传疾病等神经病进行治疗的任务。 He will support the company’s mission to advance treatments for neurological conditions like Parkinson’s, epilepsy, and rare genetic disorders. 通过FDA批准并获得CE标志的ClearPoint神经导航系统, The ClearPoint Neuro Navigation System, FDA-cleared and CE-marked, is used globally in thousands of procedures. 该公司与多个大洲的60多个合作伙伴开展合作。 The company collaborates with over 60 partners across multiple continents. 虽然公告包括关于未来疗法和伙伴关系的前瞻性声明,但实际结果可能因监管、经济和地缘政治因素而有所不同。 While the announcement includes forward-looking statements about future therapies and partnerships, actual outcomes may vary due to regulatory, economic, and geopolitical factors.